Today: 7 February 2026
Subscribe
Browse Category

NYSE:SCHD News 3 November 2025 - 3 February 2026

Schwab U.S. Dividend Equity ETF (SCHD): Latest News, Dividend Outlook and Analyst Forecasts – December 6, 2025

Schwab U.S. Dividend Equity ETF (SCHD): Latest News, Dividend Outlook and Analyst Forecasts – December 6, 2025

Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD) remains one of the most closely watched dividend ETFs going into year‑end 2025, with fresh inflows, an upcoming ex‑dividend date, and new analysis on its sector shake‑up and long‑term return potential. As of the close on December 5, 2025, SCHD’s net asset value (NAV) sits at $27.71, with roughly $71.5 billion in assets and a 0.06% expense ratio, classifying it as a large, low‑cost dividend ETF tracking the Dow Jones U.S. Dividend 100 Index. Schwab Brokerage+2ETF Database+2 Schwab reports a 30‑day SEC yield of about 3.8% and a trailing 12‑month distribution yield just
7 December 2025
··
5 Dividend ETFs That Could Pay You for Life – One Could Turn $500/Month Into $680,000

5 Dividend ETFs That Could Pay You for Life – One Could Turn $500/Month Into $680,000

Why Dividend ETFs for Lifetime Income? Dividend-focused ETFs have become go-to tools for investors seeking steady retirement income. By buying a single ETF, you get exposure to a basket of companies that regularly distribute profits to shareholders as dividends. This means instant diversification and a smoother income stream than relying on one or two stocks. These funds are managed by professionals and often track indexes of dividend-paying firms247wallst.com, so investors can “set and forget” while collecting payouts. Another appeal is stability. Dividend-paying companies tend to be established, profitable businesses (think blue-chip stocks) that can weather economic ups and downs. While
3 November 2025
····

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop